|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 August 2003, Vol. 102, No. 4, pp. 1553-1554
CORRESPONDENCE
To the editor:
Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma
The BCL10 gene, originally identified through its recurrent involvement in t(1;14)(p22;q32) of the mucosa-associated lymphoid tissue (MALT) lymphoma, encodes a cytosolic protein composed of 233 amino acid residues with proapoptotic and proinflammatory activities.1 B-cell chronic lymphocytic leukemia/lymphoma 10 (BCL10) is widely expressed in the cytoplasm of normal lymphoid tissues, with the expression level depending on the developmental stage of lymphocytes.2 Many B-cell lymphomas also express BCL10, including MALT lymphoma.2 In contrast to normal B cells that express BCL10 in the cytoplasm, MALT lymphoma cells with t(1;14)(p22;q32) or t(11;18)(q21;q21) express the protein predominantly in the nucleus.2-5 Since there are no available data on BCL10 expression in natural killer (NK) cells, we examined BCL10 expression in normal NK cells and nasal NK/T-cell lymphoma (NL) in this study.
BCL10 immunostaining was performed on the cytospin preparations of CD3–/(CD16+CD56)+ normal NK cells isolated from the peripheral blood mononuclear cells (PBMCs) of 2 healthy volunteers by cell sorting and paraffin sections of 40 NL tumor specimens using the monoclonal antibody clone 151 (1:50; Zymed, South San Francisco, CA).2 Because the NK cells were isolated from PBMCs by cell sorting, anti-(CD16+CD56) monoclonal antibodies were still bound to the antigens on the cell surface. Blocking them by a goat antimouse antibody (DAKO, Glostrup, Denmark) was performed to reduce the nonspecific binding. Immunostaining results showed BCL10 expression in NK cells and all 40 NL cases. BCL10 expression was detected only in the cytoplasm of NK cells (Figure 1A); by comparison, in addition to cytoplasmic expression, 28 (70%) of 40 NL cases showed aberrant nuclear staining of BCL10 in a variable percentage of NL tumor cells (Figure 1B). Paraffin sections of reactive tonsils were stained as controls, and only cytoplasmic staining of BCL10 was present among these tissues.
It has been previously shown that BCL10 is involved in nuclear factor– B (NF-B) activation by in vitro overexpression assay1 and by BCL10 knock-out in mice.6 Because NF-B transfer from cytoplasm to nucleus is the hallmark of its activation, we investigated NF-B localization in the same 40 NL cases by immunostaining using polyclonal antibody C-20 (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA) against NF-B p65 and compared the results with the BCL10 expression pattern in NL (Figure 1C-F). The statistical analysis of the data by the chi-square test in Table 1 showed a strong association between BCL10 nuclear localization and NF-B activation in NL (P = .001). The positive cases contained more than 10% of the tumor cells with nuclear staining.
In conclusion, our results show that BCL10 is widely expressed among normal and neoplastic NK cells and may exert the same regulatory role in NF-B signaling in NK cells as in T and B cells. Many NL tumors have the same nuclear staining of BCL10 as the MALT lymphomas, but the chromosomal abnormalities, t(1;14)(p22;q32) and t(11;18)(q21;q21), which are the hallmarks of MALT lymphoma,1-5 are not present in NL.7-8 The unexpected finding of BCL10 nuclear localization and its association with NF-B activation indicated a novel mechanism leading to aberrant BCL10 nuclear localization during tumorigenesis of NL.
Lijun Shen,
Anthony C. T. Liang,
Liwei Lu,
Wing Y. Au,
Kai-Yau Wong,
Pui-Chi Tin,
Kwok-Wah Chan,
King-Hung Ko,
Yun-Wen Chen,
Swan-Lip Beh,
Norio Shimizu,
Junjiro Tsuchiyama,
Johnny C. O. Tang,
Yok-Lam Kwong,
Raymond H. S. Liang, and
Gopesh Srivastava
Correspondence: Gopesh Srivastava, The University of Hong Kong, Department of Pathology, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong; e-mail: gopesh{at}pathology.hku.hk
Supported by a grant from the Research Grants Council of Hong Kong Special Administrative Region, PR China (HKU 7348/02M to G.S.).
References
- Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B-cell lymphoma and mutated in multiple tumor types. Cell. 1999;96: 35-45.[CrossRef][Medline]
[Order article via Infotrieve]
- Ye H, Dogan A, Karran L, et al. BCL10 expression in normal and neoplastic lymphoid tissue: nuclear localization in MALT lymphoma. Am J Pathol. 2000; 157: 1147-1154.[Abstract/Free Full Text]
- Liu H, Ye H, Dogan A, et al. t(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood. 2001;98: 1182-1187.[Abstract/Free Full Text]
- Maes B, Demunter A, Peeters B, De Wolf-Peeters C. BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression. Blood. 2002;99: 1398-1404.[Abstract/Free Full Text]
- Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 2003;101: 2547-2550.[Abstract/Free Full Text]
- Ruland J, Duncan GS, Elia A, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell. 2001; 104: 33-42.[CrossRef][Medline]
[Order article via Infotrieve]
- Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK-cell lymphoma/leukaemia. Br J Haematol. 1997;98: 922-926.[CrossRef][Medline]
[Order article via Infotrieve]
- Wong N, Wong KF, Chan JK, Johnson PJ. Chromosomal translocations are common in natural killer-cell lymphoma/leukemia as shown by spectral karyotyping. Hum Pathol. 2000;31: 771-774.[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Shen, W.-Y. Au, K.-Y. Wong, N. Shimizu, J. Tsuchiyama, Y.-L. Kwong, R. H. Liang, and G. Srivastava
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells
Mol. Cancer Ther.,
December 1, 2008;
7(12):
3807 - 3815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
Ann. Onc.,
December 1, 2008;
19(12):
2079 - 2083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Shen, W.-Y. Au, T. Guo, K.-Y. Wong, M. L. Wong, J. Tsuchiyama, P.-W. Yuen, Y.-L. Kwong, R. H. Liang, and G. Srivastava
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation
Blood,
July 1, 2007;
110(1):
469 - 470.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Rueda, O. Gaide, L. Ho, E. Lewkowicz, F. Niedergang, S. Hailfinger, F. Rebeaud, M. Guzzardi, B. Conne, M. Thelen, et al.
Bcl10 Controls TCR- and Fc{gamma}R-Induced Actin Polymerization
J. Immunol.,
April 1, 2007;
178(7):
4373 - 4384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
